Cantor Fitzgerald Reiterates Overweight on Trulieve Cannabis, Maintains $15 Price Target
Cantor Fitzgerald analyst Gabie Ingoglia reiterates Trulieve Cannabis (NYSE:TRLV) with a Overweight and maintains $15 price target.
Share
Why It Matters
A big investment firm still thinks Trulieve is a good bet. They believe the stock could be worth around fifteen dollars per share.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.